At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 303 enrolled
Drug / intervention
exenatide, long acting release +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications
In Brief
A Phase 3 clinical trial evaluating exenatide, long acting release and exenatide for Type 2 Diabetes Mellitus. Completed, enrolled 303 participants across 25 sites in 2 countries.
Detailed Summary
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2006
Enrollment StartApr 2006
Primary CompletionJul 2008
Study CompletionAug 2014
TodayJul 2026
First PostedMar 29, 2006
Enrollment StartApr 1, 2006
Primary CompletionJul 1, 2008
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.3 years ago
Interventions
exenatide, long acting releasedrug
exenatidedrug